Literature DB >> 7919453

Lean body mass, body surface area and epirubicin kinetics.

W C Cosolo1, D J Morgan, E Seeman, A S Zimet, J J McKendrick, J R Zalcberg.   

Abstract

For a number of cytotoxics, a relationship between efficacy and plasma concentrations has recently been demonstrated. Lean body mass has been demonstrated to be a useful parameter for predicting drug clearance for a number of non-cytotoxic drugs. However, the role of lean body mass in predicting drug clearance for any cytotoxic drug has not been previously reported. Our purpose was to investigate lean body mass as a predictor of epirubicin clearance. Pharmacokinetic studies were performed in 10 patients receiving single agent epirubicin. Although preliminary, this study suggests that lean body should be further evaluated and tested in dose optimization studies.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7919453     DOI: 10.1097/00001813-199406000-00005

Source DB:  PubMed          Journal:  Anticancer Drugs        ISSN: 0959-4973            Impact factor:   2.248


  7 in total

Review 1.  Body surface area as a determinant of pharmacokinetics and drug dosing.

Authors:  M Sawyer; M J Ratain
Journal:  Invest New Drugs       Date:  2001-05       Impact factor: 3.850

2.  Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B-cell lymphoma treated with CHOP-based chemotherapy.

Authors:  Daphne Y Xiao; Suhong Luo; Katiuscia O'Brian; Arun Ganti; Peter Riedell; Kristen M Sanfilippo; Ryan C Lynch; Weijian Liu; Kenneth R Carson
Journal:  Am J Hematol       Date:  2016-07-22       Impact factor: 10.047

3.  Prevalence and prognostic effect of sarcopenia in breast cancer survivors: the HEAL Study.

Authors:  Adriana Villaseñor; Rachel Ballard-Barbash; Kathy Baumgartner; Richard Baumgartner; Leslie Bernstein; Anne McTiernan; Marian L Neuhouser
Journal:  J Cancer Surviv       Date:  2012-10-04       Impact factor: 4.442

Review 4.  Epirubicin: a review of its efficacy as adjuvant therapy and in the treatment of metastatic disease in breast cancer.

Authors:  D Ormrod; K Holm; K Goa; C Spencer
Journal:  Drugs Aging       Date:  1999-11       Impact factor: 3.923

Review 5.  Epirubicin. An updated review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of breast cancer.

Authors:  A J Coukell; D Faulds
Journal:  Drugs       Date:  1997-03       Impact factor: 9.546

6.  Factors affecting the pharmacokinetic profile of MS-275, a novel histone deacetylase inhibitor, in patients with cancer.

Authors:  Milin R Acharya; Judith E Karp; Edward A Sausville; Kyunghwa Hwang; Qin Ryan; Ivana Gojo; Jurgen Venitz; William D Figg; Alex Sparreboom
Journal:  Invest New Drugs       Date:  2006-09       Impact factor: 3.850

7.  What is the effect of adjusting epirubicin doses for body surface area?

Authors:  N A Dobbs; C J Twelves
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.